WallStreetZenWallStreetZen

NASDAQ: ACRX
Acelrx Pharmaceuticals Inc Stock

$1.24+0.13 (+11.71%)
Updated Jun 9, 2023
ACRX Price
$1.24
Fair Value Price
$3.30
Market Cap
$13.55M
52 Week Low
$0.55
52 Week High
$7.60
P/E
0.2x
P/B
0.95x
P/S
5.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.33M
Earnings
$48.28M
Gross Margin
-36%
Operating Margin
3,696.09%
Profit Margin
3,234%
Debt to Equity
0.85
Operating Cash Flow
-$25M
Beta
1.04
Next Earnings
Aug 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ACRX Overview

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACRX ($1.24) is undervalued by 62.45% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACRX ($1.24) is significantly undervalued by 62.45% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more ACRX due diligence checks available for Premium users.

Be the first to know about important ACRX news, forecast changes, insider trades & much more!

ACRX News

Valuation

ACRX fair value

Fair Value of ACRX stock based on Discounted Cash Flow (DCF)
Price
$1.24
Fair Value
$3.30
Undervalued by
62.45%
ACRX ($1.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACRX ($1.24) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

ACRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.2x
Industry
14.23x
Market
52.94x
ACRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ACRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

ACRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.95x
Industry
1.76x
ACRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACRX's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
ACRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ACRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$26.3M
Liabilities
$12.1M
Debt to equity
0.85
ACRX's short-term assets ($17.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACRX's short-term assets ($17.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ACRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.3M
Investing
$400.0k
Financing
-$2.1M
ACRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ACRX vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ACRX$13.55M+11.71%0.20x0.95x
SBFM$12.40M-2.10%-0.33x0.64x
BFRI$11.91M-1.98%-0.77x0.71x
CLVR$11.52M+0.40%-0.19x0.31x
PAVS$10.99M-2.53%-0.10x0.20x

Acelrx Pharmaceuticals Stock FAQ

What is Acelrx Pharmaceuticals's quote symbol?

(NASDAQ: ACRX) Acelrx Pharmaceuticals trades on the NASDAQ under the ticker symbol ACRX. Acelrx Pharmaceuticals stock quotes can also be displayed as NASDAQ: ACRX.

If you're new to stock investing, here's how to buy Acelrx Pharmaceuticals stock.

What is the 52 week high and low for Acelrx Pharmaceuticals (NASDAQ: ACRX)?

(NASDAQ: ACRX) Acelrx Pharmaceuticals's 52-week high was $7.60, and its 52-week low was $0.55. It is currently -83.68% from its 52-week high and 125.45% from its 52-week low.

How much is Acelrx Pharmaceuticals stock worth today?

(NASDAQ: ACRX) Acelrx Pharmaceuticals currently has 10,924,294 outstanding shares. With Acelrx Pharmaceuticals stock trading at $1.24 per share, the total value of Acelrx Pharmaceuticals stock (market capitalization) is $13.55M.

Acelrx Pharmaceuticals stock was originally listed at a price of $91.00 in Feb 11, 2011. If you had invested in Acelrx Pharmaceuticals stock at $91.00, your return over the last 12 years would have been -98.64%, for an annualized return of -30.09% (not including any dividends or dividend reinvestments).

How much is Acelrx Pharmaceuticals's stock price per share?

(NASDAQ: ACRX) Acelrx Pharmaceuticals stock price per share is $1.24 today (as of Jun 9, 2023).

What is Acelrx Pharmaceuticals's Market Cap?

(NASDAQ: ACRX) Acelrx Pharmaceuticals's market cap is $13.55M, as of Jun 10, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Acelrx Pharmaceuticals's market cap is calculated by multiplying ACRX's current stock price of $1.24 by ACRX's total outstanding shares of 10,924,294.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.